ORLANDO, FL USA (UroToday.com) - Although BCG remains the intravesical therapy of choice, after TURBT, for high-grade non-muscle invasive bladder carcinomas (NMIBC), a recurrence and progression rate of up to 40% occurs after induction treatment. BCG failure likely can be attributed, at least partially, to inherent tumoral characteristics.